Trial Profile
A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2023
Price :
$35
*
At a glance
- Drugs Lanifibranor (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Acronyms NATIVE
- Sponsors Inventiva Pharma
- 14 Nov 2023 Results assessing the correlation between ADP increase and lanifibranor for histological features of NASH severity, and biomarkers of active NASH and fibrosis, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 26 Jun 2023 Results evaluating ADP at BL, ADP fold-change at EOT, and correlation between ADP change and response of markers, presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 24 Jun 2023 Results assessing correlation betweensteatosis and CMH markers at baseline (BL) and between steatosisreduction with lanifibranor and improvement of CMH markers presented at the European Association for the Study of the Liver Congress 2023